Prometrium and Liver Function: What Every Woman on HRT Needs to Know

Why the Type of Progestogen Matters for Your Liver

Not all progestogens behave the same way in your liver. Synthetic progestins such as medroxyprogesterone acetate (MPA) and norethindrone acetate are structurally altered to survive hepatic first-pass, which makes them potent but also more likely to produce cholestatic changes, alter clotting factors, and suppress HDL cholesterol. Micronized progesterone, sold under the brand name Prometrium, is bio-identical to the progesterone your ovaries produce. Because it is chemically identical to endogenous progesterone, its hepatic handling is qualitatively different.

The landmark Postmenopausal Estrogen/Progestin Interventions (PEPI) trial followed 875 postmenopausal women over three years and found that conjugated equine estrogen combined with micronized progesterone preserved the most favorable lipid profile of all treatment arms, including a significantly higher HDL-C compared to the MPA arm. No clinically meaningful hepatotoxicity signal emerged in that population. That single data point from a randomized controlled trial distinguishes Prometrium from older synthetic progestins in ways that matter for women with borderline liver enzymes or a personal history of cholestasis.

The First-Pass Effect: What Happens in Your Liver After a Capsule

When you swallow a Prometrium capsule, it dissolves in the peanut oil-based vehicle and is absorbed through the gastrointestinal tract. CYP3A4 enzymes in the intestinal wall and liver convert roughly 70-90% of oral micronized progesterone into two primary metabolites: allopregnanolone (a potent GABA-A receptor positive modulator) and pregnanolone. This extensive first-pass metabolism explains why oral progesterone has sedative properties and why serum progesterone peaks only at 1-3 ng/mL after a 200 mg oral dose, despite the relatively large dose.

The practical implication: because so much drug is converted before reaching systemic circulation, the liver sees a high local concentration of progesterone for a brief period after each dose, then clears it quickly. This is pharmacologically different from synthetic progestins engineered to resist hepatic degradation.

How CYP3A4 Induction and Inhibition Change the Picture

Drugs that induce CYP3A4 (rifampin, carbamazepine, St. John's Wort) will accelerate progesterone clearance, reducing serum levels and potentially leaving the endometrium inadequately protected. Drugs that inhibit CYP3A4 (ketoconazole, clarithromycin, grapefruit juice in large amounts) may modestly increase progesterone exposure. The FDA-approved prescribing information for Prometrium lists CYP3A4 inducers and inhibitors as drug interactions requiring clinical attention, though severe adverse reactions from this interaction are not well documented in women taking standard HRT doses.

Liver Enzyme Changes: What the Data Actually Show

Clinically significant liver enzyme elevation from Prometrium is uncommon. Rare. Understanding the difference between a transient biochemical blip and true drug-induced liver injury (DILI) is where the clinical nuance lives.

AST, ALT, and Alkaline Phosphatase

Mild transient elevations in AST and ALT have been reported in fewer than 1% of women in post-marketing surveillance. These elevations typically appear in the first 4-8 weeks of treatment, are asymptomatic, and resolve spontaneously without dose change in the majority of cases. Alkaline phosphatase is generally unaffected because Prometrium does not appear to produce significant intrahepatic cholestasis at standard HRT doses, unlike some 17-alkylated oral androgens or norethindrone acetate at high doses.

Bilirubin and Cholestasis Risk

Oral estrogen does carry a small but real risk of intrahepatic cholestasis of pregnancy-like changes in susceptible women, and this risk is the primary reason clinicians sometimes prefer transdermal estradiol in women with Gilbert syndrome or a history of intrahepatic cholestasis of pregnancy. Progesterone itself has a modest independent role in biliary motility: endogenous progesterone slows gallbladder contractility, which is part of why gallstone risk rises during pregnancy and on oral HRT. Prometrium at HRT doses contributes to this effect, though the absolute magnitude is smaller than what estrogen alone produces.

Comparing Prometrium to Synthetic Progestins in Liver Parameters

| Parameter | Prometrium (micronized P4) | MPA | Norethindrone acetate | |---|---|---|---| | HDL-C effect | Neutral to slight positive | Suppresses HDL | Suppresses HDL | | LDL-C effect | Neutral | Slight increase | Variable | | Triglycerides | Neutral | Slight increase | Slight reduction | | Cholestatic risk | Low | Low-moderate | Low-moderate | | DILI reports (post-marketing) | Rare | Rare | Rare | | CYP3A4 substrate | Yes, extensive | Partial | Partial |

The lipid differences are not trivial. In the PEPI trial, women on conjugated estrogen plus micronized progesterone had HDL-C levels averaging 5.6 mg/dL higher than baseline at three years, a difference that was statistically and likely clinically meaningful for cardiovascular risk. MPA largely negated the estrogen-driven HDL benefit.

Women With Pre-Existing Liver Conditions

This is where the evidence thins and clinical judgment matters most.

Active Hepatitis and Cirrhosis

Prometrium is contraindicated in women with active hepatic disease or a history of hepatic dysfunction according to the FDA prescribing label. The physiological reasoning is straightforward: CYP3A4 activity is markedly reduced in Child-Pugh B and C cirrhosis, which will both increase systemic progesterone exposure and reduce conversion to neurosteroid metabolites, altering the drug's effects in unpredictable ways. In women with established cirrhosis, the sedative allopregnanolone metabolite in particular raises concern for precipitating or worsening hepatic encephalopathy, a complication of end-stage liver disease. There are no controlled trial data in women with cirrhosis using Prometrium at HRT doses, which is an important evidence gap.

Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD)

NAFLD (now commonly called metabolic dysfunction-associated steatotic liver disease, MASLD) is prevalent among peri- and post-menopausal women, partly because the estrogen decline of menopause shifts fat distribution toward visceral adiposity and alters hepatic lipid handling. The relationship between HRT and MASLD progression is an area of active research. A 2023 analysis in the journal Menopause suggested that combined estrogen-progestogen therapy may be associated with lower MASLD severity scores compared to no HRT in post-menopausal women, though causal conclusions require cautious interpretation from observational data. Prometrium specifically has not been tested in randomized trials focused on MASLD endpoints.

Intrahepatic Cholestasis of Pregnancy History

Women who experienced intrahepatic cholestasis of pregnancy (ICP) are often counseled to avoid oral estrogen-containing hormonal contraceptives because of the risk of re-triggering cholestasis. The evidence on micronized progesterone in this population is limited. Endogenous progesterone itself contributes to ICP pathogenesis by impairing bile acid transport via the ABCB4 gene pathway, which means oral progesterone supplementation could theoretically worsen cholestasis in susceptible women. RCOG guidelines on ICP management do not specifically address post-menopausal HRT choices in ICP survivors, making this a shared decision-making conversation rather than a clear contraindication.

Gilbert Syndrome

Gilbert syndrome (benign unconjugated hyperbilirubinemia) is common, affecting approximately 3-7% of the population. Because it does not impair CYP3A4 activity and does not affect conjugated bilirubin pathways materially, Prometrium can generally be used without dose modification. Baseline bilirubin may be mildly elevated, but this does not worsen on standard HRT doses in the published case series.

Life-Stage Guide: Prometrium and Your Liver Across Hormonal Transitions

Perimenopause (Ages Roughly 45-52)

During perimenopause, progesterone production becomes erratic before estrogen does. Some women experience irregular cycles, heavy bleeding, or luteal-phase deficiency before frank menopause. Prometrium is sometimes prescribed cyclically (200 mg nightly for 12-14 days per month) to regulate cycles and protect the endometrium from estrogen-unopposed stimulation. Liver considerations at this stage are similar to those in post-menopause, but because these women are still cycling, interactions with endogenous hormone fluctuations add complexity. Women in this stage who have elevated transaminases from any cause (including fatty liver related to perimenopausal weight gain) should have a baseline liver panel before starting therapy.

Post-Menopause

The most common clinical scenario for Prometrium. Women using systemic estrogen therapy who have an intact uterus require a progestogen to prevent endometrial hyperplasia. The Menopause Society (formerly NAMS) 2022 position statement on hormone therapy recommends micronized progesterone as the preferred progestogen for most women because of its neutral metabolic and liver profile. Continuous combined regimens (100 mg nightly) or sequential regimens (200 mg for 12-14 days per cycle) are both used; the sequential regimen produces higher peak hepatic exposure per cycle but shorter duration.

Trying to Conceive and Fertility Treatment

Prometrium 200-600 mg vaginally (not orally) is widely used for luteal-phase support in IVF cycles. Vaginal administration largely bypasses hepatic first-pass, producing high local uterine concentrations with minimal liver exposure. In this setting, liver function impact is negligible. A Cochrane review on luteal phase support in IVF confirmed progesterone's efficacy for this indication without identifying liver-related harms as a concern in the vaginal-delivery trials.

Postpartum and Lactation

Prometrium is not a standard postpartum therapy. However, women with luteal-phase deficiency or those using progesterone for threatened miscarriage prevention may breastfeed. Progesterone transfers minimally to human milk, and physiologic maternal progesterone levels in early postpartum are already low, so infant exposure from standard oral doses is expected to be negligible. No neonatal adverse events attributable to maternal oral micronized progesterone have been documented in the lactation pharmacology literature.

Pregnancy and Lactation Safety (Required Clinical Section)

Prometrium is contraindicated during pregnancy when used for the indication of endometrial protection on HRT. The FDA classifies Prometrium in the original pregnancy category D based on data showing that progestogens as a class have been associated with genital anomalies in male fetuses when given in the first trimester, though the absolute risk from micronized progesterone specifically is low and the data are primarily derived from synthetic progestins.

The paradox worth understanding: micronized progesterone is also used therapeutically during early pregnancy (for luteal support in IVF and for cervical length reduction to prevent preterm birth at 200 mg vaginally in high-risk pregnancies). These uses are evidence-based and FDA-referenced, but they involve different doses, routes, and indications than HRT.

For women on Prometrium for HRT who could conceive (perimenopausal women who have not had 12 consecutive months of amenorrhea), reliable contraception is necessary. ACOG Practice Bulletin No. 141 on the management of menopausal symptoms underscores that perimenopausal women retain fertility even with irregular cycles and must not assume HRT provides contraceptive protection. It does not.

If pregnancy is confirmed during Prometrium HRT use, stop the medication and contact your clinician promptly. The absolute risk of fetal harm from brief first-trimester exposure at HRT doses appears low based on the totality of evidence, but the drug is not approved for that indication and should not be continued.

Regarding lactation: a breastfeeding woman should discuss with her clinician whether HRT is appropriate. Estrogen-containing HRT can suppress milk supply, a consideration independent of Prometrium's liver profile. Progesterone alone at low doses is less likely to affect lactation, but HRT as a combination is generally deferred until weaning.

Who Prometrium Is Right For (and Who Should Pause)

This framework integrates liver status with life stage and comorbidity for clinical decision-making.

Good candidates:

• Post-menopausal women with an intact uterus needing endometrial protection on systemic estrogen
• Women with a personal or family history of cardiovascular disease where the HDL-neutral or HDL-positive profile of micronized progesterone is preferable to MPA
• Women with mild, stable, compensated chronic liver disease (e.g., well-managed autoimmune hepatitis in remission) after hepatology co-management sign-off
• Women with Gilbert syndrome or incidentally elevated unconjugated bilirubin who tolerate standard HRT doses

Use with caution or consider alternatives:

• Women with active or decompensated liver disease (Child-Pugh B or C): the prescribing label lists this as a contraindication
• Women with a history of ICP who are considering HRT: discuss with a provider experienced in both menopause and liver medicine
• Women on strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): serum progesterone levels may fall below the threshold needed for endometrial protection; vaginal progesterone or dose adjustment may be necessary
• Women with a peanut allergy: Prometrium capsules contain peanut oil and are contraindicated in this population

Alternatives when Prometrium is not appropriate:

• Vaginal progesterone (Endometrin, Crinone): bypasses liver entirely; liver-disease patients are the clearest candidates
• Transdermal or intravaginal progesterone formulations where available (limited FDA-approved options for endometrial protection outside fertility)
• Levonorgestrel-releasing IUD (Mirena) for local endometrial protection in women who cannot take any systemic progestogen

Monitoring: When to Check Liver Function Tests on Prometrium

Routine LFT monitoring is not required by the FDA label or current menopause society guidelines in healthy women. The The Menopause Society clinical protocol for HRT initiation does not recommend baseline or surveillance LFTs in the absence of clinical indications.

A practical evidence-based approach for women without pre-existing liver disease:

• Baseline LFTs if the woman has a history of hepatitis, known elevated enzymes, heavy alcohol use, MASLD, or is on any hepatotoxic co-medication
• Repeat LFTs at 3 months if baseline was abnormal or borderline (AST/ALT > 1.5 times the upper limit of normal)
• No routine surveillance if baseline is normal and no new symptoms develop
• Recheck promptly for symptoms of liver dysfunction: new right upper quadrant pain, jaundice, dark urine, severe fatigue disproportionate to prior baseline

Any woman whose ALT or AST rises above 3 times the upper limit of normal on repeat testing should have Prometrium stopped and a hepatology referral placed, following standard DILI assessment criteria.

Prometrium vs. Vaginal Progesterone: The Liver Bypass Option

The first-pass effect that defines oral Prometrium's liver exposure is completely absent with vaginal progesterone. When progesterone is delivered vaginally, the uterine first-pass effect produces high endometrial tissue concentrations with serum progesterone levels approximately 10-fold lower than after an equivalent oral dose. Studies using transvaginal micronized progesterone (e.g., Crinone 4% and 8% gel) in fertility treatment consistently show negligible systemic absorption compared to the oral route.

For HRT endometrial protection specifically, vaginal micronized progesterone at 45-100 mg daily has been studied in small trials and shows adequate endometrial protection with a favorable safety profile, though it is not formally FDA-approved for this indication in the United States. Women with liver disease who genuinely need endometrial protection may benefit from a compounding pharmacy formulation or from considering the levonorgestrel IUD, which delivers local progestogen with virtually no hepatic exposure.

A Note on the Evidence Gap for Women

Women have been historically underrepresented in pharmacokinetic and hepatology trials. Most of what is known about progesterone's hepatic metabolism derives from studies of mixed populations, from fertility medicine (where the patients are younger and generally healthy), or from the PEPI trial (which studied post-menopausal women but did not include women with liver disease). The specific question of how Prometrium behaves in women with various degrees of hepatic impairment has not been studied in a rigorous controlled fashion. Clinicians managing women with moderate liver disease and menopausal symptoms are working from general pharmacological principles and case-based experience rather than randomized trial data. This gap deserves acknowledgment, not glossing over.